The role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications

Trends Cardiovasc Med. 2017 May;27(4):239-246. doi: 10.1016/j.tcm.2016.11.002. Epub 2016 Nov 19.

Abstract

Cardiovascular disease (CVD) is a health problem of great concern to both the public and medical authorities. Low-density lipoprotein (LDL) has been reported to play an important role in both the development and progression of CVD, but studies are underway to determine how LDL exerts its effects. In recent years, it has been found that LDL has several subfractions, each of which affects endothelial function differently; L5, the most electronegative fraction, has been shown to be unique in that it induces an atherogenic response. This review examines the current knowledge concerning the relationships between L5 and CVD and highlights the role of L5 in the pathophysiology of CVD, especially with regards to atherosclerosis.

Keywords: Cardiovascular disease; Electronegative low-density lipoprotein; L5.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Dyslipidemias / blood*
  • Dyslipidemias / complications
  • Dyslipidemias / diagnosis
  • Dyslipidemias / drug therapy
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Lipoproteins, LDL / blood*
  • Risk Factors
  • Scavenger Receptors, Class E / metabolism
  • Signal Transduction
  • Up-Regulation

Substances

  • Biomarkers
  • Hypolipidemic Agents
  • Lipoproteins, LDL
  • OLR1 protein, human
  • Scavenger Receptors, Class E
  • low-density lipoprotein L5, human
  • oxidized low density lipoprotein